Squamous Cell Lung Cancer - SUNY Downstate Medical Center of Lung.pdf · 10% of patients with lung...

D A N I E L K I M , M D S U N Y D O W N S T A T E M E D I C A L C E N T E R

A U G U S T 2 1 , 2 0 1 4

Squamous Cell Lung Cancer

www.downstatesurgery.org

Case Presentation

73 year old male PMH: COPD, PVD, RA 2005 -BCC of nose 2012 -SCC of right neck enlarged LN

PSH: 2005 -Excision of BCC of nose 2012 –Right neck LN biopsy followed by chemo-radiation Jan 2014 –Bronchoscopy, thoracotomy, RLL lobectomy and biopsies

of hilar LN and diaphragm

Social: Quit tobacco 2012

Case Presentation

Exam Well-developed and thin Skin exam was unremarkable Chest clear to auscultation; incisions well-healed Abdomen soft and non-tender No cervical, axillary or supraclavicular lymphadenopathy Extremities unremarkable

Laboratory 138

103 16

1.1 74

8.6 4.5

6.5 271

SUV 6.8

Pathology

January 2014 5cm SCC Moderately differentiated Extends to visceral pleural surface but margins are negative Focal vascular wall invasion Negative hilar LN (0/1) Stage (T2a, N0, M0) 1b

Postoperative Course

Uneventful hospital course in January 2014

Discharged on POD #8

No complaints per patient

Surveillance PET-CT performed 6 months later…

SUV 7.7

Bronchoscopy with Mediastinoscopy

Bronchoscopy and Mediastinoscopy with lymph node biopsies lymphadenopathy at station 4 and station 7

Patient discharged without complication POD #0

Pathology Region 7 – metastatic SCC Region 4 - negative

Mediastinoscopy

Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non–small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial Gail E. Darling, MD,a Mark S. Allen, MD,b Paul A. Decker, MS,b Karla Ballman, PhD,b Richard A. Malthaner, MD,c Richard I. Inculet, MD,c David R. Jones, MD,d Robert J. McKenna, MD,e Rodney J. Landreneau, MD,f Valerie W. Rusch, MD,g and Joe B. Putnam, Jr, MDh

Does mediastinal lymph node dissection improve survival when compared to lymph node sampline for N0 or N1 NSCLC?

Prospective Randomized Controlled Clinical Trial June 1999 to February 2004; 1023 met criteria (63 institutes) Sampling performed in 498 vs dissection in 525 patients At median followup at 6.5 years, 43% of the eligible patients

have died and there is no difference in survival; although not statistically significant (8.1 years vs. 8.5 years; P=0.25)

Questions www.downstatesurgery.org

Squamous Cell Carcinoma of the Lungs

Epidemiology Clinical Presentation Diagnosis Treatment NCCN guidelines Questions

Epidemiology

Lung cancer is the leading cancer killer in the United States

30% of all cancer deaths in the United States Diagnosed at an advanced stage of disease Lack of adequate adjuvant therapy

The overall 5-year survival for all patients with lung cancer is 15%

SCC accounts for 30 to 40% of lung cancers

Figure 19-18? A graphical chart?

Stage TNM Description Five-Year Survival

I 70–76%

a T1, N0 80–83%

b T2, N0 60–65%

II 30–40%

a T1, N1 32–40%

b T2, N1 28–35%

T3, N0

IIIA 10–30%

T3, N1 30–45%

T1–2, N2 7–30%

T3, N2 0–5%

IIIB <10%

T4, any N <10%

Any T, N3 <10%

IV M1 <5%

Overall 14.5%

Epidemiology

Survival of patients with lung cancer varies according to several demographic and social factors

Positive survival factors (5-year survival) Female sex (18.3% vs. 13.8%; F:M) Younger age (22.8% vs. 13.7%; <45 years vs. >65 years) White race (16.1% vs. 12.2%; Whites vs. African Americans) When access to advanced medical care is unrestricted ,the

racial difference in survival disappears

Epidemiology

Cigarette smoking is the primary cause of lung cancer 75% of all lung cancers worldwide in 2007 SCC is rare in non-smokers

Smoking Status Relative Risk for SCC

Current 16

Quit 1-9 years 6

Quit > 10 years 2

Non-smoker 1

Epidemiology

Other factors to consider: Biology

Chromosome deletions, Tumor suppressor gene mutations, overexpression, protooncogenes

Chemicals

Asbestos and flammable compounds: Air polution, construction, shipyard, truckers, cooks, cosmetologists, miners, etc.

Vitamin A deficiency

Certain diseases [scleroderma] have a defined predisposition for the

development of lung cancer

Clinical Presentation is Diverse

Central >> Peripheral location Regional spread and Metastatic Disease Paraneoplastic Syndromes

Locations: Right > Left; and Upper > Lower/Middle 7% with Synchronous primary lung cancers 10% develop a metachronous tumor (2%/year risk)

Central vs. Peripheral Lung Tumors

Central Tumors – 80% Cough Wheezing Stridor Dyspnea Hemoptysis Pain Pneumonia

Peripheral Tumors – 20% Cough Chest wall pain Effusion Abscess Horner Syndrome -ipsilateral miosis, ptosis, anhidrosis Pancoast syndrome -ipsilateral shoulder and arm pain in the C8-T1 nerve root distribution

Regional and Metastatic Disease

Regional Disease Hoarseness -Recurrent nerve paralysis Dysphagia -Compression of esophagus SVC syndrome -Invasion/compression of SVC Pericardial Tamponade -Invasion of pericardium

Metastatic Disease Constitutional: -Anorexia -Weight loss -Weakness /Malaise Pulmonary and hilar lymph nodes Mediastinal lymph nodes Lung Liver (Jaundice) Bone (25%) Brain (10-25%) Adrenal glands Pancreas Kidney Soft tissues (8%) Myocardium

Paraneoplastic Syndromes

Hypercalcemia 10% of patients with lung cancer and is most often due to

metastatic disease 15% of cases are caused by secretion of ectopic

parathyroid hormone–related peptide, most often with squamous cell carcinoma

A diagnosis by measurement of elevated serum levels of parathyroid hormone

Symptoms of hypercalcemia include lethargy, depressed level of consciousness, nausea, vomiting, and dehydration

Paraneoplastic Syndromes

Peripheral and central neuropathies 16% of all Lung cancer patients

SCC causes 25% of these cases

Immune mediated; Cancer cells express antigens of the nervous system

and are targeted by immune cells

CNS metastases must be ruled out with CT or magnetic resonance imaging (MRI) of the head for patients with neurologic or muscular symptoms

Diagnosis and Treatment

A new solitary pulmonary nodule on CXR 20 - 40% chance of being malignant > 50% chance of malignancy in smokers. A new primary lung cancer is most common in patients with a

history of uterine carcinoma (74%), bladder carcinoma (89%), lung carcinoma (92%), and head and neck carcinoma (94%)

Radiologic factors suggestive of cancer Growth over time Size >3cm Non-calcified Irregular, lobulated, or spiculated edges Solid > partial-solid > non-solid nodules

Lung cancers have volume-doubling times of 20 to 400 days

Lesions with shorter doubling times are likely due to infection

Longer doubling times suggest benign tumors but can indicate slower-growing lung cancer

Picture of scc lung ct scan

Algorithm for Diagnosis and Treatment

History and Physical Smoking history Pulmonary history Cancer history Environmental or occupational exposure Infectious exposure Examination of head/neck/oropharynx

CXR CT Chest Laboratory

Incidental Solitary Pulmonary Nodule

<8mm – observe with 6-month CT chest

>8mm solid and non-calcified – obtain PET-CT Low suspicion: 3-month CT Higher suspicion: Biopsy / Excision

>10mm part solid and non solid – observe with 3-6 month CT

If stable; consider repeat CT or biopsy/excision If growing; proceed with bronchoscopy and excision

Objectives Evaluate tissue Evaluate for metastatic disease Assess suitability of patient for resection and lung volume

reduction surgery

NSCLC (Non-Small Cell Lung Cancer) or highly suspicious nodule Bronchoscopy for proximal lesions VATs preferred over FNA for peripheral lesions

Fewer complications and lower false negative rate

Preoperative assessment for lung reduction surgery PFTs Cardiac workup if necessary

Clinical Staging CT chest/abdomen/pelvis MRI brain PET-CT Mediastinal lymph node evaluation

Algorithm for Diagnosis and Treatment www.downstatesurgery.org

Contraindications to Pulmonary Resection

Absolute Relative

Myocardial infarction within previous 3 months

Myocardial infarction within previous 6 months

SVC syndrome (due to metastatic tumor) SVC syndrome (due to primary tumor) Bilateral endobronchial tumor Recurrent laryngeal nerve paralysis (due to

primary tumor in aorticopulmonary window)

Contralateral lymph node metastases (N3) Horner syndrome Malignant pleural effusion Small cell histology Distant metastases (except solitary brain and adrenal metastases)

Metastases higher than the midtracheal lymph nodes

Pericardial involvement FEV1 < 0.8 L (< 50%) FEV1 0.9–2.4 and insufficient pulmonary reserve for planned resection

Main pulmonary artery involvement

Stage Ia, Ib, Exploration, resection with bronchoscopy, mediastinoscopy

and lymph node biopsies Adjuvant chemotherapy for high-risk biology (poorly

differentiated) or incomplete sampling of nodes R0 resections are considered for chemotherapy R1-2 resections receive re-resection and RT +/- chemo

Stage IIa, IIb Same as Stage Ia-b R0 resections receive chemotherapy R1-2 resections receive re-resection and chemo-RT

Lobectomy (mortality 2.9%) is the standard of care for resection. Include a 1-cm margin of normal proximal bronchus

Frozen section: Interlobar (hilar) lymph nodes Pneumonectomy (mortality 6.2%) is required for

proximal lesions involving the main stem bronchus or the interlobar (hilar) lymph nodes

Complications: cardiac arrhythmias, hemorrhage, infection (empyema), bronchopleural fistula, respiratory insufficiency, and pulmonary embolism

Stage IIIa and IIIb Preoperative workup should include MRI spine and thoracic

inlet for lesions Resectable tumors with bronchoscopy receive Chemo+/-RT

postoperatively Consideration for induction Chemotherapy Unresectable tumors receive Chemo-RT R1-2 resections receive Chemo-RT

Algorithm for Diagnosis and Treatment www.downstatesurgery.org

Stage IV Disease The treatment of patients with stage IV disease is

chemotherapy and radiation Very limited resections may be performed for metastatic

disease (solitary nodules to the brain, adrenals, etc.) Growing use of radiation therapy and chemotherapy

Chemotherapy

Study CT Regimen Radiation Therapy 5-year Survival CT vs. Control

Italian Stage IB Study Cis/Etoposide × 6 No 63% vs. 45%

IALT LeChevalier Various platinum Yes ± 44.5% vs. 40.4%

CALGB 9633 Strauss Carbo/Taxol × 4 No 69% vs. 54%

JBR.10 Alam Vin/P × 4 No 71% vs. 59%2

Table 18–11. Adjuvant Trials Favoring Use of Chemotherapy in Completely Resected Non–Small Cell Lung Cancer.1 1CT, Carbo/Taxol, carboplatin paclitaxel; Vin/P, vinorelbine cisplatin; Cis, cisplatin. 24-year survival statistics.

Questions www.downstatesurgery.org

Test Questions

Question 1/4

A 59-year-old man who underwent removal of a malignant tumor 2 years earlier has a solitary lung nodule 1.5 cm in diameter. For this patient to be considered an operative candidate, which of the following criteria must be met?

A. The tumor doubling time must be longer than 40 days. B. Even if effective systemic therapy is available, resection of metastatic lesions is preferred.

C. Recurrence at the primary site must be managed before therapy for metastatic disease is begun.

D. If pulmonary reserve is marginal, resection of the maximal number of metastatic foci should be performed.

E. It must be possible to control extrathoracic metastasis with another modality, such as radiation therapy or reexcision.

Question 1/4

A 59-year-old man who underwent removal of a malignant tumor 2 years earlier has a solitary lung nodule 1.5 cm in diameter. For this patient to be considered an operative candidate, which of the following criteria must be met?

A. The tumor doubling time must be longer than 40 days. B. Even if effective systemic therapy is available, resection of metastatic lesions is preferred.

C. Recurrence at the primary site must be managed before therapy for metastatic disease is begun…Correct!

D. If pulmonary reserve is marginal, resection of the maximal number of metastatic foci should be performed.

E. It must be possible to control extrathoracic metastasis with another modality, such as radiation therapy or reexcision.

Question 2/4

A 4-cm peripheral squamous cell carcinoma of the lung of a 60-year-old man with a pleural effusion positive for malignant cells would be classified by the tumor, node, metastasis (TNM) system as: A) T3N0M1b B) T1aN0M1a C) T2aN0M1a D) T3N0M0 E) T4N0M1a.

Question 2/4

A 4-cm peripheral squamous cell carcinoma of the lung of a 60-year-old man with a pleural effusion positive for malignant cells would be classified by the tumor, node, metastasis (TNM) system as: A) T3N0M1b B) T1aN0M1a C) T2aN0M1a…..Correct! D) T3N0M0 E) T4N0M1a.

Question 3/4

A 42-year-old man has a solitary "coin lesion" 2 cm in diameter in the area of the right upper lobe on a routine chest radiograph. Which of the following statements is true?

A. Calcification in a concentric or "popcorn" configuration denotes a malignant lesion B. A radiograph from 5 years earlier shows the lesion to be 1.2 cm in diameter and suggests malignant growth C. In the absence of previous radiographs, the lesion should be followed by serial radiographs every 6 months D. Needle aspiration that yields "chronic inflammatory cells" denotes a benign lesion E. If computed tomography shows mediastinal adenopathy, mediastinoscopy is preferable to thoracotomy.

Question 3/4

A 42-year-old man has a solitary "coin lesion" 2 cm in diameter in the area of the right upper lobe on a routine chest radiograph. Which of the following statements is true?

A. Calcification in a concentric or "popcorn" configuration denotes a malignant lesion B. A radiograph from 5 years earlier shows the lesion to be 1.2 cm in diameter and suggests malignant growth C. In the absence of previous radiographs, the lesion should be followed by serial radiographs every 6 months D. Needle aspiration that yields "chronic inflammatory cells" denotes a benign lesion E. If computed tomography shows mediastinal adenopathy, mediastinoscopy is preferable to thoracotomy…Correct

Question 4/4

A 55-year-old man who is a long-term smoker has a 2-cm, irregular, noncalcific lesion in the right upper peripheral lung on a routine chest x-ray. The only abnormality seen on computed tomographic (CT) scan is the peripheral nodule. He is asymptomatic except for nightly low-grade fevers. Bronchoscopy is negative. Management should include:

A. skin tests for tuberculosis and fungi B. excision of the lesion C. Mediastinoscopy D. trial of antibiotic therapy E. careful observation with serial chest x-rays

Question 4/4

A 55-year-old man who is a long-term smoker has a 2-cm, irregular, noncalcific lesion in the right upper peripheral lung on a routine chest x-ray. The only abnormality seen on computed tomographic (CT) scan is the peripheral nodule. He is asymptomatic except for nightly low-grade fevers. Bronchoscopy is negative. Management should include:

A. skin tests for tuberculosis and fungi B. excision of the lesion…Correct! C. Mediastinoscopy D. trial of antibiotic therapy E. careful observation with serial chest x-rays

Squamous Cell Lung Cancer - SUNY Downstate Medical Center of Lung.pdf · 10% of patients with lung...

Documents

Systemic Therapy of Metastatic Non-Small Cell Lung Cancer · LUNG CANCER CONFERENCE 2017 RICHARD A HENSON CANCER INST SYSTEMIC THERAPY OF NON-SMALL CELL LUNG CANCER: 2017 LUNG CANCER

Lung cancer

Living with lung cancer - Roy Castle Lung Cancer Foundationdocuments.roycastle.org/AYQ-LivingWithLungCancer... · Living with lung cancer and Managing lung cancer symptoms , along

CT Lung Cancer Screening - Memorial Hospital · CT Lung Cancer Screening ... (ACR) Lung Cancer Committee Subgroup ... absence of signs or symptoms of lung cancer -Reporting System:

SMALLCELL LUNG%CANCER - - · PDF fileThere are two major types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)

Lung cancer

MONOGRAPH ON LUNG CANCER - Lung Center of the …lcp.gov.ph/images/Scientific_Proceedings/Monograph_on_Lung_Cancer_July14.pdfMONOGRAPH ON LUNG CANCER: LUNG CANCER REGISTRY DATA OF

Chemotherapy for lung cancer - Roy Castle Lung Cancer

Lung Cancer Quality Performance Indicators: Descriptions › cancer-services › lung-cancer-qpis › ... · LUNG CANCER QUALITY PERFORMANCE INDICATORS: DRAFT DESCRIPTIONS FOR REVIEW

lung cancer What is cancer of the lung?

Lung Cancer Screening & Smoking Cessation · Lung Cancer Screening – Transformative Change in Lung Cancer Care •Lung cancer is the most common cause of cancer death worldwide

Honeycomb Lung: History and Current Conceptssudhirstomorrow.yolasite.com/resources/Honeycomb lung.pdf · AJR:196, April 2011 775 Imaging of Honeycomb Lung In another study, honeycomb

Lung - Frank's Hospital Workshopfrankshospitalworkshop.com/.../wikipedia/Lung.pdf · Lung 1 Lung The lungs of a pig ... Vital capacity is the maximum volume of air that a person can

Better Living with Lung Cancer - Lung Foundationlungfoundation.com.au/.../2014/01/Better-Living-with-Lung-Cancer.pdf · Better Living with Lung Cancer A Patient Guide. 2 Lung Cancer

By: Ashish, Andy, and Megan. Lung Cancer What is Lung Cancer? Lung Cancer is the most common type of cancer

Lung Cancer Screening and Staging - USI | Bachelor … 2 Lung Cancer: Epidemiology •Lung cancer is the second most common cancer in the United States •Lung cancer is the #1 cause

09 Lung.pdf